IgA anti-beta-2 glycoprotein I antibodies in chronic hepatitis C

Melayah, Sarra; Kallala, Ouafa; Ahmed, M.; Fodha, I.; Jemni, S.; Ghedira, Ibtissem; Mankaï, Amani

doi:10.1016/j.ajg.2021.12.003

Cited by 4 publications

(8 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the current study, ACL antibodies, which are considered one of the serological hallmarks of antiphospholipid antibody syndrome, were detected in 78.9% of the sera of children with HCV. The frequency of ACL antibodies in our patients with chronic HCV was higher than that recorded by Melayah (51%) [8] and Leroy et al (20.9%) [9].…”

Section: Autoantibodies In Liver Diseasescontrasting

confidence: 70%

Autoantibodies: are they a clue for liver diseases?

Nagi¹,

Ayoub²,

Ali³

et al. 2022

ceh

View full text Add to dashboard Cite

Introduction: Autoantibody testing has contributed to both biological and clinical insights in managing patients with liver disease. These autoantibodies often have clinical value for the diagnosis, disease activity and/or prognosis. Aim of the study:We aimed to investigate the potential application of auto-antibodies in different etiologies of non-autoimmune liver diseases. Material and methods: This study was conducted on 53 infants and children with chronic liver diseases. The patients were subjected to clinical history and examination, laboratory investigations and abdominal ultrasound. Serum of all infants and children was tested for measurement of antiprothrombin antibody and anti-β2-glycoprotein I (aβ2GPI) and anticardiolipin (ACL) auto-antibodies using a fully-automated enzyme linked immunosorbent assay (ELISA) system. Results: The mean age of the infants with cholestatic liver diseases was significantly lower than those with metabolic liver diseases, hepatitis C virus (HCV) and vascular liver diseases (p < 0.05). The gender distribution was proportionate in all groups (p = 0.703). Autoantibodies showed significant variations among different etiologies of chronic liver diseases. The incidence of aβ2GPI and ACL was significantly increased in both HCV (94.7% and 78.9%, respectively) and vascular liver diseases patients (90.9% and 72.7%, respectively) (p < 0.05). Antiprothrombin antibodies were found in 81.8% of vascular liver disease patients. Interestingly, all types of autoantibodies were deficient in cholestatic and metabolic liver diseases. Conclusions: Testing for liver-related autoantibodies should be included in the workup of patients with chronic liver diseases. Further studies are needed to explain the cause-effect association of ACL, aβ2GPI and antiprothrombin with chronic HCV and vascular liver diseases.

show abstract

Section: Autoantibodies In Liver Diseasescontrasting

confidence: 70%

Autoantibodies: are they a clue for liver diseases?

Nagi¹,

Ayoub²,

Ali³

et al. 2022

ceh

View full text Add to dashboard Cite

show abstract

“…Indeed, molecular mimicry between structure of the infectious agents and β2GPI molecule induce an autoimmune response and synthesis of aβ2GPI by a break-down of the tolerance. 29 Besides, we demonstrated, in our recent study, an elevated frequency of aβ2GPI-IgA in patients with hepatitis C. 17 Bold value is statistically significant.…”

Section: Discussionmentioning

confidence: 69%

“…many autoimmune diseases (AID) other than APS including rheumatoid arthritis (RA), 13 autoimmune hepatitis, 14 celiac disease, 15 primary biliary cholangitis, 16 and in infectious diseases like hepatitis C 17 and coronavirus disease 2019 (COVID-19). 18 All these autoimmune and infectious diseases may include rheumatic manifestations.…”

mentioning

confidence: 99%

Anticardiolipin and anti‐beta 2‐glycoprotein I antibodies in patients with unexplained articular manifestations

Melayah

Ghozzi

Ghedira

et al. 2022

Clinical Laboratory Analysis

Self Cite

View full text Add to dashboard Cite

Objective To determine the frequency of antiphospholipid antibodies (aPL) in patients with unexplained articular manifestations. Material and Methods Three hundred thirteen patients suffering from arthritis or arthralgia without evident cause and 266 healthy blood donors (HBD) were included in the study. Anticardiolipin antibodies (aCL) and anti‐beta 2‐glycoprotein I antibodies (aβ2GPI) were measured by ELISA. Result Out of the 313 patients, 250 were females and 63 were males. The mean age of patients was 49 ± 14 years (17–87 years). One hundred eleven patients have arthralgia and 202 have arthritis. The frequency of aCL and/or aβ2GPI (24.9%) was significantly higher in patients than in HBD (10.9%). The frequency of aβ2GPI was 23.6% in patients and 9.4% in the control group (p < 10−3). aβ2GPI‐IgA was significantly more frequent in patients than in the control group (20.4% vs. 7.5%, p < 10−3). aβ2GPI was most commonly observed than aCL in patients (23.6% vs. 6.4%, p < 10−6). IgA isotype of aβ2GPI was the most frequent in 20.4% of patients while IgG and IgM were detected in 5.4% and 2.9% respectively. Conclusion This study showed that aPL were common in patients with articular manifestations and were mainly directed against β2GPI. The role of these antibodies remains to be specified.

show abstract

“… 35 Interestingly, we have previously reported a higher frequency of aβ2GPI‐IgA in chronic hepatitis C patients compared to healthy controls. 36 Since hepatitis C antibodies have been described to be frequent in Tunisia 3.32%, 37 so, could we imagine that the high frequency found in the present study is due to hepatitis C virus? In addition to environmental triggers of HT, the microbiota has been described as involved in thyroid autoimmunity.…”

Section: Discussionmentioning

confidence: 79%

“…35 Interestingly, we have previously reported a higher frequency of aβ2GPI-IgA in chronic hepatitis C patients compared to healthy controls. 36 Since hepatitis C antibodies have been…”

Section: Why Are the Aβ2gpi Synthesized In Ht?mentioning

confidence: 99%

Antiphospholipid antibodies in autoimmune thyroid diseases

Mankaï

Melayah

Bousetta

et al. 2022

Clinical Laboratory Analysis

Self Cite

View full text Add to dashboard Cite

Background Antiphospholipid (aPL) antibodies have been reported in several autoimmune diseases. The aim of this study was to evaluate the frequency of aPL (anti‐cardiolipin antibodies (aCL) and anti‐β2 glycoprotein I antibodies (aβ2GPI)) in patients with autoimmune thyroid diseases (AITD). Methods One hundred and ninety‐five patients with AITD (139 Hashimoto's thyroiditis (HT) patients and 56 Graves' disease (GD) patients) and 90 healthy blood donors (HBD) were studied. IgG, IgA and IgM aCL and aβ2GPI were determined by ELISA. Results One hundred fifty‐four AITD patients were women and 41 were men. Fifty‐six healthy subjects were women and 34 were men. The median age of patients and the control group was 45 and 38.5 years, respectively. The frequency of aPL was significantly higher in patients with AITD and in patients with HT than in HBD (33.3% vs 11.1%, p < 10−3 and 38.1% vs 11.1%, p < 10−3). The frequency of aPL in GD was significantly lower than in HT (21.4% vs 38.1%, p = 0.025). In patients with HT, aβ2GPI (34.5%) was significantly more frequent than aCL (13.6%) (p < 10−3). The frequency of aβ2GPI was significantly higher in patients with HT than in healthy population (34.5% vs 11.1%, p < 10−3). In HT patients, IgA isotype of aβ2GPI was significantly more common than in HBD and in GD patients (27.3% vs 7.8%, p < 10−3 and 27.3% vs 12.5%, p = 0.02, respectively). Conclusion aβ2GPI and not aCL were frequent in AITD. IgA was the predominant isotype of aβ2GPI. aβ2GPI‐IgA was more frequent in HT than in GD.

show abstract

IgA anti-beta-2 glycoprotein I antibodies in chronic hepatitis C

Cited by 4 publications

References 27 publications

Autoantibodies: are they a clue for liver diseases?

Autoantibodies: are they a clue for liver diseases?

Anticardiolipin and anti‐beta 2‐glycoprotein I antibodies in patients with unexplained articular manifestations

Antiphospholipid antibodies in autoimmune thyroid diseases

Contact Info

Product

Resources

About